Table 4 The laboratory follow-up of COVID-19 Patients During the Monitoring Period. Abu Dhabi, 2020
Variables | PB-NHESC-C treated | Control | p-valueb | |||||
|---|---|---|---|---|---|---|---|---|
Time | n | Median (95% CI) | p-valuea | n | Median (95% CI) | p-valuea | ||
White blood cells (109/L) | 1st | 51 | 6.8 (4, 20.45) | 0.5377 | 35 | 6.855 (3.199, 13.45) | 0.0753 | 0.0174* |
2nd | 7.6 (3.84, 18.76) | 10.99 (4.006, 24.5) | ||||||
Neutrophils (109/L) | 1st | 51 | 4.4 (1.6, 17.75) | 0.2251 | 35 | 4.49 (1.812, 12) | 0.3023 | 0.0029** |
2nd | 4.3 (1.5, 15.18) | 7.27 (2.21, 22.65) | ||||||
Lymphocytes (109/L) | 1st | 51 | 1.305 (0.55, 3.2) | < 0.0001*** | 35 | 1.305 (0.5205, 3.46) | 0.068 | 0.0017** |
2nd | 2.1 (0.802, 3.38) | 1.64 (0.38, 2.758) | ||||||
Monocytes (109/L) | 1st | 51 | 0.6 (0.3, 1.25) | 0.9838 | 35 | 0.535 (0.1355, 1.078) | 0.0017** | 0.019* |
2nd | 0.6 (0.3, 1.504) | 0.88 (0.302, 1.852) | ||||||
Eosinophils (109/L) | 1st | 51 | 0.1 (0, 0.3) | < 0.0001*** | 35 | 0.075 (0.00, 0.4155) | 0.0074** | 0.3378 |
2nd | 0.2 (0, 0.82) | 0.18 (0.00, 0.81) | ||||||
Basophils (109/L) | 1st | 51 | 0.0 (0, 0.1) | < 0.0001*** | 35 | 0.02 (0.00, 0.0645) | 0.0109* | 0.3925 |
2nd | 0.1 (0, 0.2) | 0.03 (0.00, 0.158) | ||||||
NLR (U) | 1st | 51 | 3 (0.86, 15.66) | 0.0011** | 35 | 2.6 (0.84, 15.7) | 0.5764 | < 0.0001*** |
2nd | 1.8 (0.56, 16.79) | 4.3 (1.1, 57.66) | ||||||
D-Dimer (μg FEU/mL) | 1st | 49 | 0.4 (0.2, 8.1) | 0.1113 | 31 | 0.57 (0.21, 14.8) | 0.3931 | < 0.0001*** |
2nd | 0.2 (0, 3.6) | 1.51 (0.26, 537.7) | ||||||
Fibrinogen (g/dL) | 1st | 31 | 718 (380, 1136) | < 0.0001*** | 13 | 420 (240, 1940) | 0.0625 | < 0.0001*** |
2nd | 350 (220, 69) | 470 (390, 980) | ||||||
IL-6 (pg/mL) | 1st | 31 | 20.3 (1.5, 3361) | < 0.0001*** | 0 | ND | ND | ND |
2nd | 3.05 (1.4, 3384) | ND | ||||||
C-reactive protein (mg/L) | 1st | 31 | 34 (0.6, 381.8) | < 0.0001*** | 24 | 21.79 (0.4, 335.3) | 0.0049** | 0.0048** |
2nd | 3.6 (0.42, 111) | 16.45 (0.6, 350) | ||||||